BioSpace News Archive

Terumo Blood and Cell Technologies (Terumo), a medical technology company, and Eliaz Therapeutics Inc. (ETI), a medical device company, today announced an exclusive collaboration to help combat AKI and S-AKI by focusing on the selective removal of an upstream inflammatory protein called Galectin-3 (Gal-3) from blood plasma.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 on Wednesday, August 3, 2022, after the market closes.

Health Canada is providing an update on the progress of Philips Respironics’ recall of several models of CPAP and BiLevel PAP machines and mechanical ventilators in Canada.

OneTouchPoint, Inc. (“OTP”) is providing notice of an incident that may affect the privacy of certain individuals’ personal information.

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its initial public offering of 2,000,000 shares of the Company’s common stock at a public offering price of $5.00 per share for aggregate gross proceeds of $10,000,000 prior to deducting underwriting discounts, commissions, and other offering expenses.

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the interim safety and efficacy data of dose expansion cohort from the phase I study of TST001.

Myovant Sciences announced financial results for the first quarter of fiscal year 2022 and provided other corporate updates.

Amedisys, Inc. reported its financial results for the three and six-month periods ended June 30, 2022.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), today announced its financial results for the second quarter and six months ended June 30, 2022, and provided an update on its clinical pipeline and other corporate developments.

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter financial results on Wednesday, August 3, 2022, at 8:30 a.m. ET.